Amy Holthaus

Responsible for the development and optimization of primary and immortalized immune cell assays to study the interaction of drug candidate inhibitors with T cells, B cells, and monocytes. • Screening of CROs for cell assay transfer • Mentoring and training of summer undergraduate intern

Flagship Labs-91 was merged with Ampersand Biomedicines in March 2023. Developed various immune cell assays (T cells, B cells and monocytes) to characterize antibody drug conjugates. Also, developed a profiling cytokine assay to demonstrate the mechanism of action of novel drug modalities in human primary monocytes along with a human macrophage polarization assay to assess the activity of drug candidates. • Multi-plex ELISA (MSD) for cytokine profiling • Key contributor to the company’s functional biology team; project co-lead • Optimized PD-1 immune checkpoint reporter assay • Led PBMC procurement and isolation of immune cell populations

Flagship Labs-91 was merged into Ampersand Biomedicines in March 2023. Please see description for Ampersand Biomedicines for role/responsibilities.

Developed a Myeloid-derived suppressor cell (MDSC) assay to screen candidate cytokines; early data showed T cell suppression reversal. Also optimized and developed cytotoxicity assays to compare various candidate molecules for multiple preclinical programs including luminescence and cell imaging readouts. • Multi-color (parameter) Flow Cytometry with analysis • Immune cell isolation: monocytes, T cells, myeloid cells, and NK cells • Cell culture: cancer cell lines, HEK293 and immune cells • ELISA development including creation of a cell-based ELISA • Antibody binding/blocking titration assays on engineered cell lines (expressing human and NHP genes of interest)

Early cell line development and in vitro clotting assays for FDA approved drug Altuviiio (rFVIIIFc-VWF-XTEN). This included the creation and development of 100+ cell lines stably expressing biologics candidates and optimizing their protein expression levels, enabling down-stream experiments leading to go/no-go program decisions. • Managed all the hemophilia transient transfections; responsible for maintaining the master cell lines, predominantly suspension and adherent HEK293 and CHO • Extraction of RNA/DNA from mammalian cell lines with RT/qPCR analysis • Created an electronic cell line registry and database, including curating 1,000+ historical cell lines • Consistently designed new protocols, along with optimizing and troubleshooting experiments • Member of Bioverativ spinoff transition team, managing space allocation, supply procurement, and selection of electronic laboratory notebook • Regularly presented updates to team members and upper management on status of projects

Biogen spun-off the Hematology department in February 2017 creating Bioverativ. Bioverativ was acquired by Sanofi in March 2018. Please see the description under Sanofi for roles/responsibilities.

Biogen spun-off the Hematology department in February 2017 creating Bioverativ. Bioverativ was acquired by Sanofi in March 2018. Please see the description under Sanofi for roles/responsibilities.

Designed and executed a model system for the study of smooth muscle genes in lymphoblastoid cell lines. Along with the optimization of Cyclic-AMP fluorescence ELISA for drug treatment experiments. • Trained junior technicians on experimental protocols and molecular biology techniques. • Piloted the generation of HaloPlex DNA enrichment libraries for next-generation sequencing (NGS) and implemented automation protocol. • Independent experimental design, result analysis, and data presentation.

Generated lymphoblastoid cell lines (LCLs) transformed by recombinant EBV expressing tandem affinity tagged EBV nuclear antigen (EBNA) proteins. Identified three novel EBNA3 associated proteins by tandem affinity purification and further characterized those interactions; resulting in a co-first authorship of a PLOS Pathogens publication. • Designed and optimized standard research specific protocols including troubleshooting experiments • Trained and mentored summer undergraduate students and new lab members

Researched the effects of NO2 as an oxidizing agent to form platinum (IV) complexes from platinum (II) complexes for drug delivery.

Concentration in Inorganic Chemistry

Concentration in Human Anatomy